Sedative, haemodynamic and respiratory effects of dexmedetomidine in children undergoing magnetic resonance imaging examination: preliminary results

A. Koroglu*, S. Demirbilek, H. Teksan, O. Sagir, A. K. But and M. O. Ersoy

Department of Anaesthesiology and Reanimation, Medical Faculty, Inonu University, Malatya, Turkey

* Corresponding author: akoroglu{at}inonu.edu.tr

Accepted for publication February 8, 2005.


    Abstract
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
Background. We evaluated the sedative, haemodynamic and respiratory effects of dexmedetomidine and compared them with those of midazolam in children undergoing magnetic resonance imaging (MRI) procedures.

Methods. Eighty children aged between 1 and 7 yr were randomly allocated to receive sedation with either dexmedetomidine (group D, n=40) or midazolam (group M, n=40). The loading dose of the study drugs was administered for 10 min (dexmedetomidine 1 µg kg–1 or midazolam 0.2 mg kg–1) followed by continuous infusion (dexmedetomidine 0.5 µg kg–1 h–1 or midazolam 6 µg kg–1 min–1). Inadequate sedation was defined as difficulty in completing the procedure because of the child's movement during MRI. The children who were inadequately sedated were given a single dose of rescue midazolam and/or propofol intravenously. Mean arterial pressure (MAP), heart rate (HR), peripheral oxygen saturation () and ventilatory frequency (VF) were monitored and recorded during the study.

Results. The quality of MRI was significantly better and the rate of adequate sedation was higher in group D than in group M (P<0.001). In group D, the requirement for rescue drugs was lower and the onset of sedation time was shorter than in group M (P<0.001). MAP, HR and VF decreased from baseline during sedation in both groups (P<0.001).

Conclusions. Dexmedetomidine provided adequate sedation in most of the children aged 1–7 yr without haemodynamic or respiratory effects during MRI procedures.

Keywords: brain, magnetic resonance imaging ; sedation, paediatrics ; sedative, dexmedetomidine


    Introduction
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
Children may be frightened by being in the magnetic resonance imaging (MRI) tunnel or duct and the loud noise generated during the imaging process. Thus sedation is required for children aged between 1 and 7 yr.1 2 MRI examination is very sensitive to motion artifacts. If any movement occurs during the imaging process for one sequence, the entire sequence must be repeated.2 Children may not remain immobile for long enough to allow a sequence to be completed. Consequently, a deep level of sedation is required during MRI.1 2 Deep sedation is defined as ‘a medically induced state of central nervous system depression in which the patient is essentially unconscious, and so does not respond to verbal command’. The potential complications of deep sedation include hypoventilation, apnoea, airway obstruction, aspiration, hypotension, bradycardia, and increased intracranial pressure. If any complications occur during an MRI examination, the nature of the set-up precludes easy access to the patient.1 3

There has been debate over the appropriate drugs and dosage regimens for MRI sedation in children.1 Dexmedetomidine is a potent highly selective {alpha}2-adrenoreceptor agonist with a distribution half-life of approximately 8 min and a terminal half-life of 3.5 h.4 5 Dexmedetomidine, as a sedative agent, can provide easily controllable analgesia and sedation without respiratory depression57 and has been widely used in the intensive care unit (ICU) for sedation and postoperative analgesia.8 9 Its use for sedation in children in situations outside the operating theatre or ICU has not been studied, other than in a few case reports.1012

In this preliminary study, the aim was to improve sedation and develop a regimen based on dexmedetomidine, and to evaluate the sedative, haemodynamic and respiratory effects of dexmedetomidine compared with midazolam in children undergoing MRI examination.


    Methods
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
After local institutional ethics committee approval and written parental consent, 80 ASA I–II children aged 1–7 yr undergoing MRI were included in this randomized prospective study. Patients with heart, lung or neurological disease, central nervous system or extremity trauma, or contraindication or allergy to any of the drugs studied, or who had received any study drug in the last 30 days were excluded. All children were allowed to take clear liquids up to 2 h before sedation but food (including milk) intake was withheld for at least 8 h in children >36 months, and for 6 h in children aged 12–36 months. To facilitate i.v. cannulation, EMLA cream was applied on the dorsum of both hands 1 h before transfer to the preparation room. Presedation behaviour was assessed on a four-point scale (1=calm, cooperative; 2=anxious but reassurable; 3=anxious and not reassurable; 4=crying or resisting) by a team member blinded to the drug allocation (anaesthetist 1). Categories 1 and 2 were classed as undistressed and categories 3 and 4 as distressed. Baseline values were recorded upon arrival in the preparation room. A 22G or 24G venous cannula was inserted in the dorsum of the hand. Children were allocated according to a random number table to either the study group receiving dexmedetomidine (group D, n=40) or the control group receiving midazolam (group M, n=40). Dexmedetomidine (Precedex®, Abbott Laboratories, North Chicago, IL, USA) and midazolam (Dormicum®, Roche, Basel, Switzerland) were prepared by a team member not involved in data recording (anaesthetist 2). One millilitre of dexmedetomidine 100 µg ml–l was diluted with 49 ml normal saline to a concentration of 2 µg ml–l. Two millilitres of midazolam 5 mg ml–l were diluted with 48 ml normal saline to a concentration of 200 µg ml–l. A loading dose (dexmedetomidine 1 µg kg–1 or midazolam 0.2 mg kg–1) was given over 10 min followed by continuous infusion (dexmedetomidine 0.5 µg kg–1 h–1 or midazolam 6 µg kg–1 min–1).

The sedation level was measured every 10 min using the Ramsay sedation scale13 by evaluating response to sound, verbal commands or tactile stimulation by anaesthetist 1. The Ramsay scale assigns a score of 1–6 based on the clinical assessment of the level of sedation (1=anxious, agitated, restless; 2=awake, but cooperative, tranquil, orientated; 3=responds to verbal commands only). Scores 4–6 apply to sleeping patients and are graded according to the response to loud noise or a glabellar tap (4=brisk response; 5=sluggish response; 6=no response). The children were taken into the MRI room after a Ramsay score of 6 and haemodynamic and respiratory stability were achieved. If a Ramsay score of 6 was not achieved after infusion of the study drug for 25 min, the infusion rate was increased by anaesthetist 2 to 0.7 µg kg–1 h–1 in group D and 8.4 µg kg–1 min–1 in group M for 5 min. If a Ramsay score of 6 was not achieved after 25+5 min of study drug infusion or inadequate sedation occurred during MRI examination, a single rescue dose of midazolam 0.05 mg kg–1 i.v. was given. If this was not sufficient, propofol 0.5 mg kg–1 i.v. was administered 3 min after the rescue dose of midazolam. Inadequate sedation was defined as difficulty in completing the procedure because of movement during MRI examination.

Mean arterial pressure (MAP), heart rate (HR), peripheral oxygen saturation () and ventilatory frequency (VF) were monitored continuously by anaesthetist 1 and recorded at 5-min intervals during the study period. Spontaneous respiration was maintained in all children. If fell below 93% for 30 s, oxygen was given via a facemask.

The quality of the MRI examination was evaluated by a radiologist using a three-point scale (1=no motion; 2=minor movement; 3=major movement necessitating another scan). At the end of the MRI, drug infusion was discontinued and the children were transferred to the recovery room.

The onset of sedation time was defined as the time from starting drug infusion to achieving a Ramsay score of 6. Recovery time was the time between discontinuation of drug infusion and reaching a Ramsay score of 2. Discharge time was the time between discontinuation of drug infusion and discharge of the child from the unit. Discharge criteria were the return of vital signs and level of consciousness to baseline, and the ability to maintain a patent airway.

Statistical analyses were made using SPSS® 10.0 (SPSS Inc., Chicago, IL, USA). Analysis of variance for repeated measures was performed on haemodynamic and respiratory parameters, with compensation for post hoc comparisons using the Bonferroni correction. Intergroup statistical analyses were performed using the t-test, and non-parametric data were analysed using the {chi}2-test. Statistical significance was assumed at P<0.05. Results are presented as mean (SD) or their 95% confidence interval (CI). Because of the lack of a primary outcome, the power of the study was calculated based on the onset of sedation time. Setting a significance level of P=0.05, it was calculated that a group size of 40 patients allowed detection of a difference between groups with a power of 100%.


    Results
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
The patient characteristics, presedation behaviour scores and duration and type of MRI procedure were not statistically different between groups. The quality of MRI was significantly better in group D than in group M (P<0.001) (Table 1). MRI examination was successfully completed in all patients and no complications were observed during or after sedation in either group.


View this table:
[in this window]
[in a new window]
 
Table 1 Patient characteristics, duration, types, quality, and details of MRI procedures. Values are mean (range) for age and mean (SD) for weight and duration of MRI, or number of children.

 
Adequate sedation was obtained in 32 children from group D (80%, 95% CI, 0.64–0.91) and in eight children from group M (20%, 95% CI, 0.09–0.36) (P<0.001). Afterinfusion of the study drug for 30 min, the median Ramsay score was 5 in eight children from group D and 4 in 34 children from group M. In these children, a Ramsay score of 6 was obtained with the rescue dose of midazolam and/or propofol before MRI examination. Inadequate sedation was observed in eight children from group D and in 32 children from group M during MRI. The eight children in group D who were inadequately sedated received a rescue dose of midazolam which was sufficient for adequate sedation during MRI. The 32 children in group M who had already received midazolam as a rescue drug also required propofol as an additional rescue drug during MRI. The requirement of rescue drugs was significantly lower in group D than in group M (P<0.001). MRI examination was successfully completed in all these children. In group D, the onset of sedation was significantly shorter than in group M [19 (8.2) min vs 35 (11) min, P<0.001]. The duration of drug infusion, recovery and discharge times were not different between groups (P>0.05) (Table 2).


View this table:
[in this window]
[in a new window]
 
Table 2 Results of sedation and duration of study drug infusion. Values are mean (SD) or number of children.

 
MAP and HR were not statistically different between groups before and during sedation. They decreased significantly from baseline during sedation in both groups (P<0.001). MAP in groups D and M was 82 (7.8) mm Hg and 83 (11.0) mm Hg, respectively, before sedation, and 72 (8.1) mm Hg and 71 (7.5) mm Hg, respectively, during sedation. HR in groups D and M was 109 (12.3) beats min–1 and 113 (8.6) beats min–1, respectively, before sedation, and 96 (12.2) beats min–1 and 104 (10.5) beats min–1, respectively, during sedation. No children experienced bradycardia or hypotension during sedation. The maximum decrease in MAP during sedation in groups D and M was 16% and 17%, respectively, and the maximum decrease in HR during sedation was 15% and 10%, respectively.

VF was decreased significantly from baseline in both groups during sedation (P<0.001) but was not significantly different between groups before or during sedation. Mean VF in groups D and M was 27 (3.6) bpm and 28 (5.2) bpm, respectively, before sedation, and 25 (3.2) bpm and 24 (4.8) bpm, respectively, during sedation. The maximum decreases in VF during sedation in groups D and M were 8% and 14%, respectively. did not fall below 93% in any children in group D during the study, but VF<93% was observed in three children in group M (P>0.05) before MRI examination. These three children had been given rescue propofol because of a Ramsay score <6 before MRI examination. In these children, the decrease in was easily treated with oxygen supplementation via a facemask.


    Discussion
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
Sedation of children for MRI can be associated with difficulty in obtaining deep sedation while maintaining haemodynamic and respiratory stability remotely.1 3 Inadequate sedation during MRI occurred in 5–15% of cases, causing failure in 3.7%, and the incidence was higher in hyperactive, uncooperative and older children.3 14

Previous studies indicate that infusion of dexmedetomidine 0.1–0.7 µg kg–1 h–1 provides effective sedation.7 11 12 15 16 A sedation score between 2 and 4 was obtained with 0.5 µg kg–1 loading and 0.25–0.5 µg kg–1 h–1 infusion dose of dexmedetomidine.10 In our study, a dexmedetomidine loading dose of 1 µg kg–1 and infusion of 0.5–0.7 µg kg–1 h–1was used. Effective sedation with midazolam has been reported with loading doses of 0.2–0.5 mg kg–1 and infusion of 1–8 µg kg–1 min–1 in children.17 18 These doses are similar to our midazolam doses. Midazolam, as a sole sedative agent, has been associated with a higher incidence of failed sedation during MRI procedures, which is consistent with our results.3 It is known that midazolam has a quick onset of action and a short recovery room stay when it is administered intravenously over 2–5 min.17 However, in our study the midazolam loading dose was administered over 10 min to parallel that of the dexmedetomidine. The rate of administration of the midazolam loading dose may explain the low rate of adequate sedation rate. There were also more distressed patients before sedation in group M. Adequate sedation was obtained with dexmedetomidine in most of the children and the others were effectively sedated with rescue midazolam.

Arian and colleagues19 reported a sedation induction time of 25 min and a recovery time of 34 min with dexmedetomidine in adults. The onset of sedation time and the recovery time was shorter in our study. This could be explained by the fact that the subjects were children and that the duration of infusion was shorter.

Although the most important disadvantage of dexmedetomidine is adverse haemodynamic effects, there are conflicting reports on these.5 6 9 15 20 21 Hypotension and bradycardia have been reported, particularly with high-bolus dosing regimens, in patients with pre-existing cardiac problems and a loading dose infusion given over <10 min.4 9 22 Midazolam is said to have more haemodynamic stability,17 but in our study MAP and HR decreased significantly after both drugs. These decreases could be because of high baseline values which, in turn, could have occurred because the children were not premedicated. On the other hand, the decreases in MAP and HR were <20% from baseline and were considered to be clinically insignificant.

Respiratory events make up a large proportion (5.5%) of the complications of the sedation in children.3 Some authors have reported that dexmedetomidine had no respiratory effects,7 23 but others have described respiratory complications with large and rapid loading doses.4 21 24 A loading dose of dexmedetomidine given over 2 min caused irregular respiration, apnoea, slight hypoxaemia and hypercapnia.20 Respiratory depression and apnoea were not observed in any of the children who received dexmedetomidine during our study. The desaturation observed in three children who received midazolam may have been caused by rescue propofol.

Propofol, chloral hydrate, and midazolam have been used as sedative agents for children,1 18 and a complication rate of 20% in sedation performed for diagnostic procedures in children has been reported.3 Chloral hydrate may cause desaturation and may be associated with restlessness and prolonged imbalance.3 18 Propofol can cause respiratory depression, loss of protective airway reflexes and bradycardia in appropriate doses.25 26 Midazolam may cause paradoxical excitation and agitation with higher doses.18 In our study, no complications were seen in any child who received dexmedetomidine.

In conclusion, dexmedetomidine provided adequate sedation at 1 µg kg–1 loading and 0.5–0.7 µg kg–1 h–1 infusion doses in most of the children (aged between 1–7 yr) without affecting haemodynamics and respiration. Thus dexmedetomidine may be a suitable agent for MRI sedation in children.


    References
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
1 Lawson GR. Sedation of children for magnetic resonance imaging. Arch Dis Child 2000; 82: 150–2[Free Full Text]

2 Hasan RA, Shayevitz JR, Patel V. Deep sedation with propofol for children undergoing ambulatory magnetic resonance imaging of the brain: experience from a pediatric intensive care unit. Pediatr Crit Care Med. 2003; 4: 454–8[CrossRef][Medline]

3 Malviya S, Voepel LT, Eldevik OP et al. Sedation and general anaesthesia in children undergoing MRI and CT: adverse events and outcomes. Br J Anaesth 2000; 84: 743–8[Abstract]

4 Bhana KNL, McClellan GJ, McClellan KJ. Dexmedetomidine. Drugs 2000; 59: 263–8[ISI][Medline]

5 Shelly MP. Dexmedetomidine: a real innovation or more of the same? Br J Anaesth 2001; 87: 677–8[Free Full Text]

6 Nelson LE, Lu J, Guo T et al. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 2003; 98: 428–36[CrossRef][ISI][Medline]

7 Hall JE, Uhrich TD, Barney JA et al. Sedative, amnestic and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg 2000; 90: 699–705[Abstract/Free Full Text]

8 Venn M, Newman J, Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 2003; 29: 201–7[ISI][Medline]

9 Venn RM, Bradshaw CJ, Spencer R et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 1999; 54: 1136–42[CrossRef][ISI][Medline]

10 Ard J, Doyle W, Bekker A. Awake craniotomy with dexmedetomidine in pediatric patients. J Neurosurg Anesthesiol 2003; 15: 263–6[CrossRef][ISI][Medline]

11 Tobias JD, Berkenbosch JW. Initial experience with dexmedetomidine in paediatric-aged patients. Paediatr Anaesth 2002; 12: 171–5[CrossRef][ISI][Medline]

12 Tobias JD, Berkenbosch JW, Russo P. Additional experience with dexmedetomidine in pediatric patients. South Med J 2003; 96: 871–5[ISI][Medline]

13 Schulte-Tamburen AM, Scheier J, Briegel J et al. Comparison of five sedation scoring systems by means of auditory evoked potentials. Intensive Care Med 1999; 25: 377–82[CrossRef][ISI][Medline]

14 Voepel LT, Malviya S, Prochaska G, Tait RA. Sedation failures in children undergoing MRI and CT: is temperament a factor? Paediatr Anaesth 2000; 10: 319–23[CrossRef][ISI][Medline]

15 Triltsch AE, Welte M, Von Homeyer P et al. Bispectral index-guided sedation with dexmedetomidine in intensive care: randomized, double blind, placebo-controlled phase II study. Crit Care Med 2002; 30: 1007–14[CrossRef][ISI][Medline]

16 Dutta S, Karol MD, Cohen T et al. Effect of dexmedetomidine on propofol requirements in healthy subjects. J. Pharmacol Sci 2001; 90: 172–81[CrossRef][ISI][Medline]

17 Rosen DA, Rosen KR. Intravenous conscious sedation with midazolam in pediatric patients. Int J Clin Pract 1998; 52: 46–50[ISI][Medline]

18 Keengwe IN, Hegde S, Dearlove O, Wilson B, Yates RW, Sharples A. Structured sedation programme for magnetic resonance imaging examination in children. Anaesthesia 1999; 54: 1069–72[CrossRef][ISI][Medline]

19 Arian SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg 2002; 95: 461–6[Abstract/Free Full Text]

20 Ebert TJ, Hall JE, Barney JA et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000; 93: 382–94[CrossRef][ISI][Medline]

21 Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. Br J Anaesth 2002; 88: 669–75[Abstract/Free Full Text]

22 Kallio A, Scheinin M, Koulu M et al. Effects of dexmedetomidine, a selective alpha2-adrenoceptor agonist, on hemodynamic control mechanisms. Clin Pharmacol Ther 1989; 49: 33–42

23 Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care 2000; 4: 302–8[CrossRef][ISI][Medline]

24 Belleville JP, Wards DS, Bloor BC, Maze M. Effects of intravenous dexmedetomidine in human: sedation, ventilation and metabolic rate. Anesthesiology 1992; 77: 1125–33[ISI][Medline]

25 Tramer MR, Moore RA, McQuay HJ. Propofol and bradycardia: causation, frequency and severity. Br J Anaesth 1997; 78: 642–51[Abstract/Free Full Text]

26 Aun CS. New i.v. agents for paediatric patients. Br J Anaesth 1999; 83: 29–41[Free Full Text]